As of today, 11 multi-RTK inhibitors with antiangiogenic properties are used for the treatment of advanced cancers (17), notably sorafenib and sunitinib that inhibit a large number of kinases (e.g., FGF/FGFR, cKIT, cMET, RET, PDGF/PDGFR-α/-β, FLT3) as well as VEGFR-1 and -2, and to a lesser extend VEGFR-3 (18). This evidence concerns the gene FLT4 and cancer.